Abstract
The present paper reviews and discusses selectivity of ABCC4 (MRP4), ABCC5 (MRP5) and ABCC11 (MRP8) as cellular efflux pumps for cAMP and cGMP. These transporters are potential drug targets for selective modulation of cyclic nucleotide action.
Keywords: cGMP, cAMP, ABCC4, ABCC5, ABCC11, transport selectivity
Mini-Reviews in Medicinal Chemistry
Title: Cellular Efflux of cAMP and cGMP - A Question about Selectivity
Volume: 9 Issue: 8
Author(s): Georg Sager and Aina Westrheim Ravna
Affiliation:
Keywords: cGMP, cAMP, ABCC4, ABCC5, ABCC11, transport selectivity
Abstract: The present paper reviews and discusses selectivity of ABCC4 (MRP4), ABCC5 (MRP5) and ABCC11 (MRP8) as cellular efflux pumps for cAMP and cGMP. These transporters are potential drug targets for selective modulation of cyclic nucleotide action.
Export Options
About this article
Cite this article as:
Sager Georg and Ravna Westrheim Aina, Cellular Efflux of cAMP and cGMP - A Question about Selectivity, Mini-Reviews in Medicinal Chemistry 2009; 9 (8) . https://dx.doi.org/10.2174/138955709788681654
DOI https://dx.doi.org/10.2174/138955709788681654 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
MicroRNA in the Pathogenesis and Prognosis of Esophageal Cancer
Current Pharmaceutical Design The Design of Vectors for RNAi Delivery System
Current Pharmaceutical Design Follow the ATP: Tumor Energy Production: A Perspective
Anti-Cancer Agents in Medicinal Chemistry Quinazolines as Apoptosis Inducers and Inhibitors: A Review of Patent Literature
Recent Patents on Anti-Cancer Drug Discovery Recent Patents on Novel P2X7 Receptor Antagonists and their Potential for Reducing Central Nervous System Inflammation
Recent Patents on CNS Drug Discovery (Discontinued) The Role of microRNAs in Gliomas – Therapeutic Implications
Current Molecular Pharmacology microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology Redox Regulation in the Base Excision Repair Pathway: Old and New Players as Cancer Therapeutic Targets
Current Medicinal Chemistry Nitric Oxide Synthase Potentiates the Resistance of Cancer Cell Lines to Anticancer Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Id-1B, an Alternatively Spliced Isoform of the Inhibitor of Differentiation-1, Impairs Cancer Cell Malignancy Through Inhibition of Proliferation and Angiogenesis
Current Molecular Medicine The Important Roles of miR-205 in Normal Physiology, Cancers and as a Potential Therapeutic Target
Current Cancer Drug Targets Upregulated Long Non-coding RNA ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic Cerebral Injury
Current Pharmaceutical Design Up-regulation of microRNA-16 in Glioblastoma Inhibits the Function of Endothelial Cells and Tumor Angiogenesis by Targeting Bmi-1
Anti-Cancer Agents in Medicinal Chemistry Novel Nucleic Acid-Based Agents: siRNAs and miRNAs
Central Nervous System Agents in Medicinal Chemistry Anti-Angiogenic Approaches to Malignant Gliomas
Current Cancer Drug Targets Therapeutic Use of Molecules that Mimic Pathogen Danger Signals
Endocrine, Metabolic & Immune Disorders - Drug Targets Peptide Prodrugs for the Treatment of CNS Disorders: A Perspective for New Drugs
Current Medicinal Chemistry Combination Treatment of Glioblastoma by Low-Dose Radiation and Genistein
Current Radiopharmaceuticals Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry Retinal Ganglion Cell Gene Therapy and Visual System Repair
Current Gene Therapy